Ting Chen

Dr. Ting Chen


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2020 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
JMju mingyi
ju mingyi
JBJia Bi
Jia Bi
QWQian Wei
Qian Wei
LJLongyang Jiang
Longyang Jiang
QGQiutong Guan
Qiutong Guan
LZLin Zhao
Lin Zhao
NLRP3 inflammasome was introduced as a double-edged sword in tumorigenesis and influenced immunotherapy response by modulating host immunity. However, a systematic assessment of the NLRP3-inflammasome-related genes across human cancers is lacking, and the predictive role of NLRP3 inflammasome in cancer immunotherapy (CIT) response remains unexplored. Thus, in this study, we performed a pan-cancer analysis of NLRP3-inflammasome-related genes across 24 human cancers. Out of these 24 cancers, 15 cancers had significantly different expression of NLRP3-inflammasome-related genes between normal and tumor samples. Meanwhile, Cox regression analysis showed that the NLRP3 inflammasome score could be served as an independent prognostic factor in skin cutaneous melanoma. Further analysis indicated that NLRP3 inflammasome may influence tumor immunity mainly by mediating tumor-infiltrating lymphocytes and macrophages, and the effect of NLRP3 inflammasome on immunity is diverse across tumor types in tumor microenvironment. We also found that the NLRP3 inflammasome score could be a stronger predictor for immune signatures compared with tumor mutation burden (TMB) and glycolytic activity, which have been reported as immune predictors. Furthermore, analysis of the association between NLRP3 inflammasome and CIT response using six CIT response datasets revealed the predictive value of NLRP3 inflammasome for immunotherapy response of patients in diverse cancers. Our study illustrates the characterization of NLRP3 inflammasome in multiple cancer types and highlights its potential value as a predictive biomarker of CIT response, which can pave the way for further investigation of the prognostic and therapeutic potentials of NLRP3 inflammasome.

31 July 2024 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
JMju mingyi
ju mingyi
JZJiaojiao Zhang
Jiaojiao Zhang
ZDZhuoyuan Deng
Zhuoyuan Deng
MWMinjie Wei
Minjie Wei
LZLin Zhao
Lin Zhao
LZLin Zhao
Lin Zhao
Background: Immune-related adverse events (irAEs), characterized by targeted inflammation, occur in up to 60% of patients with melanoma treated with immune checkpoint inhibitors (ICIs). Evidence proved that the baseline peripheral blood profiles of patients at risk for severe irAEs development paralleled clinical autoimmunity. Interleukin (IL)-23 blockade with risankizumab is recommended for cases that are suffering from autoimmune disease, such as autoimmune colitis. However, currently, the role of IL-23 in irAEs onset and severity remains poorly understood. Methods: The pro-inflammatory cytokines most associated with severe irAEs onset were identified by retrospective analysis based on GSE186143 data set. To investigate the efficacy of prophylactic IL-23 blockade administration to prevent irAEs, refer to a previous study, we constructed two irAEs murine models, including dextran sulfate sodium salt (DSS)-induced colitis murine model and a combined-ICIs-induced irAEs murine model. To further explore the applicability of our findings, murine models with graft-versus-host disease were established, in which Rag2−/−Il2rg−/− mice were transferred with human peripheral blood mononuclear cells and received combined cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) and programmed cell death protein-1 (PD-1) treatment. Human melanoma cells were xenografted into these mice concomitantly. Results: Here we show that IL-23 was upregulated in the serum of patients suffering from irAEs after dual anti-CTLA-4 and anti-PD-1 treatment, and increased as a function of irAEs severity. Additionally, Augmented CD4+ Tems may preferentially underlie irAEs onset. Treating mice with anti-mouse IL-23 antibody concomitantly with combined CTLA-4 and PD-1 immunotherapy ameliorates colitis and, in addition, preserves antitumor efficacy. Moreover, in xenografted murine models with irAEs, prophylactic blockade of human IL-23 using clinically available IL-23 inhibitor (risankizumab) ameliorated colitis, hepatitis and lung inflammation, and moreover, immunotherapeutic control of tumors was retained. Finally, we also provided a novel machine learning-based computational framework based on two blood-based features—IL-23 and CD4+ Tems—that may have predictive potential for severe irAEs and ICIs response. Conclusions: Our study not only provides clinically feasible strategies to dissociate efficacy and toxicity in the use of combined ICIs for cancer immunotherapy, but also develops a blood-based biomarker that makes it possible to achieve a straightforward and non-invasive, detection assay for early prediction of irAEs onset.

7 April 2023 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
HZHe Zhang
He Zhang
BHBo Hou
Bo Hou
TXTienan Xia
Tienan Xia
LJLu Ji
Lu Ji
JLJiatong Li
Jiatong Li
GSGuanning Shang
Guanning Shang
Background: There are many reconstruction methods after sternal tumor resection, but the method that LARS mesh combines with bone-cement has not been reported.Case report: A 54-year-old female patient and a 55-year-old male patient admitted to our department all presented with sternum masses, but neither presented with respiratory disorders. In women with limited manubrium sternum lesions, we resected the manubrium sternum completely. In men with sternal lesions, we removed part of the sternum and part of the sternocostal joint. The patients recovered well after surgery, and there were no respiratory complications and no tumor recurrence during the 1-year follow-up respectively.Conclusion: We report two cases of sternal defect repair using LARS mesh combined with bone cement. This method is safe and stable, and can achieve satisfactory results.

8 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GZGuangqiang Zhang
Guangqiang Zhang
JLJuntan Li
Juntan Li
TCTing Chen
Ting Chen
JLJiatong Li
Jiatong Li
KSKai Sun
Kai Sun
GSGuanning Shang
Guanning Shang
Background: Despite advances in treatment strategies, osteosarcoma patients undergoing limb-salvage surgery (LSS) still face a considerable risk of recurrence and unsatisfactory long-term survival. Therefore, reliable pretreatment baseline prognostic assessment tools are needed to improve postoperative risk stratification and guide individualized treatment. Methods: This single-center retrospective prediction model development study analyzed 118 patients with pathologically confirmed osteosarcoma treated at Shengjing Hospital, China Medical University, between January 2019 and January 2025. After applying predefined inclusion and exclusion criteria, 81 patients were included in the final analysis. All predictors were defined as before-treatment baseline measurements at the diagnosis stage: alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) were serum biochemical markers, whereas fibrinogen (FIB) and D-dimer were plasma coagulation-related markers. Ki-67 index, age, sex, tumor size, and lung metastasis status were also assessed at this before-treatment baseline. A diagnosis-stage baseline prognostic model for overall survival (OS) among patients undergoing LSS was subsequently constructed. Internal validation of model performance was performed using bootstrap resampling only, with no external validation performed. Results: Kaplan–Meier analysis demonstrated 1-, 3-, and 5-year survival rates of 87.3%, 74.3%, and 64.1%, respectively. Survival curve analysis revealed that patients with elevated levels of all four laboratory biomarkers were associated with shorter OS. Multivariate Cox regression analysis revealed that baseline ALP remained independently associated with OS, while FIB showed borderline significance (p = 0.050). The final OS prognostic model incorporated ALP, LDH, FIB, and D-dimer. The apparent Harrell’s concordance index (C-index) of the model was 0.838 for the full dataset, with an optimism-corrected C-index of 0.780 after Bootstrap internal validation. The area under the receiver operating characteristic curve (AUC) of the model for predicting 1-, 3-, and 5-year OS in the full dataset was 0.831, 0.864, and 0.871, respectively; the optimism-corrected AUC values after Bootstrap validation were 0.771, 0.810, and 0.814. Conclusions: In this single-center retrospective cohort, higher baseline levels of ALP, LDH, FIB, and D-dimer were associated with adverse clinicopathological characteristics and poorer survival outcomes in patients with osteosarcoma. The LASSO-Cox-based prognostic model showed promising discrimination and calibration after internal Bootstrap validation. However, given the limited sample size and absence of external validation, these findings should be considered preliminary, and prospective multicenter external validation is required before the model can be considered for routine clinical implementation.